CRD-B
Crawford & Company
There isn't enough reported data to score CRD-B yet.
JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
CRD-B Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
CRD-B's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CRD-B.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
CRD-B PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $11.49 | — |
| Cheap | 12x | $8.64 | -25% |
| Fair | 19x | $13.43 | +17% |
| Current | 22x | $11.49 | — |
| Expensive | 29x | $21.04 | +83% |
Historical ranges are pointers, not guarantees.
CRD-B has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
CRD-B Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect CRD-B's earnings to grow, with its revenue and profitability holding steady.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
JPM has the edge over CRD-B on the outlook, with more favorable revenue and profitability expectations.
CRD-B Earnings Per Share
CRD-B and JPM do not have enough comparable growth data to identify a winner.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
CRD-B Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $329.9M | -0.9% |
| Q2 2026 | $330M | -1.4% |
| Q1 2026 | $320.1M | -1% |
| Q4 2025 | $320.1M | -11% |
| Q3 2025 | $332.8M | -2.9% |
| Q2 2025 | $334.6M | +2.4% |
| Q1 2025 | $323.3M | +3.3% |
| Q4 2024 | $358.3M | +12% |
CRD-B's revenue grew through 2022 and has held roughly level since: $330M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.3% | +1.1 points |
| Q2 2026 | 6.4% | +1.6 points |
| Q1 2026 | 2.9% | -0.7 points |
| Q4 2025 | -1.3% | -4.6 points |
| Q3 2025 | 6.2% | +1.2 points |
| Q2 2025 | 4.8% | +0.1 points |
| Q1 2025 | 3.6% | +1.6 points |
| Q4 2024 | 3.4% | +3.2 points |
CRD-B's operating margin was 7.3% last quarter, up 1.1 points from the same quarter a year ago, near the top of its range since 2019.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the edge over CRD-B on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over CRD-B on profitability, with a higher operating margin.
CRD-B Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5M | -83% |
| Q2 2026 | $18.6M | -45% |
| Q1 2026 | $1.4M | +$16.3M |
| Q4 2025 | $46.9M | +26% |
| Q3 2025 | $29.3M | +65% |
| Q2 2025 | $33.6M | +188% |
| Q1 2025 | -$14.9M | +$6.4M |
| Q4 2024 | $37.3M | +9.1% |
CRD-B has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
CRD-B Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -947K shares |
| 1 year | -3.2% | -1.6M shares |
| 3 years | -2.5% | -1.2M shares |
| 5 years | -10% | -5.4M shares |
| Available history | -10% | -5.5M shares |
CRD-B has the edge over JPM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.5M |
| Q2 2026 | $3.5M |
| Q1 2026 | $5.5M |
| Q4 2025 | $7.6M |
| Q3 2025 | $3M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $263,000 |
CRD-B spent $30M buying back its own shares over the past year, about nine times what it spent the year before.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has 2.7B diluted shares, down 3.1% from a year ago, with $24.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
CRD-B Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 1.9x | Healthy |
CRD-B's net debt is about 1.6 years of its operating earnings (EBITDA), about the same as a year ago. Net leverage isn't a meaningful measure for financial services companies like CRD-B.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM has the edge over CRD-B on leverage, with a lower net debt burden relative to earnings.
CRD-B Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.8 | Neutral |
| Stochastic | 35.7 | Neutral |
CRD-B's weekly RSI is 52 (neutral) and its Stochastic is 36 (neutral).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
CRD-B PE vs Financial Services Sector
| Metric | CRD-B | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 65% above |
| PE % | 63 | 63 | Same percentile |
CRD-B is trading at 22x earnings, a 65% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM has the edge over CRD-B on valuation relative to its sector.
CRD-B Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 2.5% below |
| 20 week MA | $11.5 | 0.3% below |
| 50 week MA | $10.9 | 5.6% above |
| 100 week MA | $10.9 | 5.4% above |
| 200 week MA | $10.4 | 10% above |
CRD-B has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 10% above its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over CRD-B on trend strength, trading above more of its moving averages.
CRD-B Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.1 | $7.49 | -33% |
| 2021 | $7.49 | $7.51 | +0.3% |
| 2022 | $7.51 | $5.55 | -26% |
| 2023 | $5.55 | $13.2 | +137% |
| 2024 | $13.2 | $11.5 | -13% |
| 2025 | $11.5 | $11.9 | +3.6% |
| 2026 YTD | $11.9 | $11.5 | -3.2% |
CRD-B has finished lower in three of the last six years. It's down 3.2% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over CRD-B on returns for 2026, with the stronger performance.